Dmitry Balyasny’s Neurocrine Biosciences NBIX Stock Holding History

Dmitry Balyasny’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-50,000	Closed	-$5.63M	–	2756
2023 Q3	$5.63M	Hold	50,000	–	–	0.01%	1064
2023 Q2	$4.71M	Buy	+50,000	New	+$4.89M	0.01%	1085
2019 Q4	–	Sell	-240,000	Closed	-$21.6M	–	1373
2019 Q3	$21.6M	Buy	+240,000	New	+$22.4M	0.15%	225
2018 Q3	–	Sell	-110,400	Closed	-$10.8M	–	1922
2018 Q2	$10.8M	Buy	+110,400	New	+$9.88M	0.05%	467

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dmitry Balyasny's NBIX Position: Q1 2026 in Review

Dmitry Balyasny sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 141,101 shares — an estimated $20M sold.

Dmitry Balyasny first reported a position in NBIX in Q2 2015 and held it in 23 quarters. The position peaked at $73.1M in Q2 2023. 697 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Dmitry Balyasny reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
Dmitry Balyasny sold 141,101 Neurocrine Biosciences shares in Q1 2026, an estimated $20M.
Dmitry Balyasny first reported a position in Neurocrine Biosciences in Q2 2015 and held it in 23 quarters.
Dmitry Balyasny's Neurocrine Biosciences position peaked at $73.1M in Q2 2023.
697 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.